Cargando…

Survival outcomes of patients with germ cell tumors treated with high-dose chemotherapy for refractory or relapsing disease

INTRODUCTION: Male patients with metastatic germ cell tumors can be cured in up to 96% of cases depending on stage and IGCCCG prognosis group. Treatment in relapse consists of conventional or high-dose chemotherapy (HDCT) with autologous stem cell transplantation (ASCT) combined with local treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zschäbitz, Stefanie, Distler, Florian A, Krieger, Benjamin, Wuchter, Patrick, Schäfer-Eckart, Kerstin, Jenzer, Maximilian, Hohenfellner, Markus, Dreger, Peter, Haag, Georg Martin, Jäger, Dirk, Pahernik, Sascha, Grüllich, Carsten
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5976483/ https://www.ncbi.nlm.nih.gov/pubmed/29854297 http://dx.doi.org/10.18632/oncotarget.25162

Ejemplares similares

Prospective single center trial of next-generation sequencing analysis in metastatic renal cell cancer: the MORE-TRIAL
por: Dieffenbacher, Svenja, et al.
Publicado: (2018)

Efficacy of Cabazitaxel Treatment in Metastatic Castration Resistant Prostate Cancer in Second and Later Lines. An Experience from Two German Centers
por: Zschäbitz, Stefanie, et al.
Publicado: (2017)

Harnessing the p53-PUMA Axis to Overcome DNA Damage Resistance in Renal Cell Carcinoma()
por: Zhou, Xiaoguang, et al.
Publicado: (2014)

Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate
por: Apostolidis, Leonidas, et al.
Publicado: (2019)

The BRCA2 mutation status shapes the immune phenotype of prostate cancer
por: Jenzer, Maximilian, et al.
Publicado: (2019)

Patient-specific molecular alterations are associated with metastatic clear cell renal cell cancer progressing under tyrosine kinase inhibitor therapy
por: Dietz, Steffen, et al.
Publicado: (2017)

MET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive marker
por: Macher-Goeppinger, Stephan, et al.
Publicado: (2016)

Uncoupling of PUMA Expression and Apoptosis Contributes to Functional Heterogeneity in Renal Cell Carcinoma — Prognostic and Translational Implications()
por: Zhou, Xiaoguang, et al.
Publicado: (2015)

Mutations in BRCA2 and taxane resistance in prostate cancer
por: Nientiedt, Cathleen, et al.
Publicado: (2017)

Efficacy and Safety of Checkpoint Inhibitor Treatment in Patients with Advanced Renal or Urothelial Cell Carcinoma and Concomitant Chronic Kidney Disease: A Retrospective Cohort Study
por: Seydel, Florian, et al.
Publicado: (2021)

The ribosomal protein S6 in renal cell carcinoma: functional relevance and potential as biomarker
por: Knoll, Maximilian, et al.
Publicado: (2015)

Current Challenges in Providing Good Leukapheresis Products for Manufacturing of CAR-T Cells for Patients with Relapsed/Refractory NHL or ALL
por: Korell, Felix, et al.
Publicado: (2020)

Paclitaxel-containing high-dose chemotherapy for relapsed or refractory testicular germ cell tumours
por: McNeish, I A, et al.
Publicado: (2004)

Successful Outcome of Autologous Stem Cell Transplantation for Relapsed or Refractory Germ Cell Tumors
por: Mousavi, Seied Aasadollah, et al.
Publicado: (2018)

Prognostic Significance and Functional Role of CEP57 in Prostate Cancer()
por: Mang, Josef, et al.
Publicado: (2015)

eHealth intervention to manage symptoms for patients with cancer on immunotherapy (SOFIA): a study protocol for a randomised controlled external pilot trial
por: Sauer, Christina, et al.
Publicado: (2021)

Paraganglioma of the Seminal Vesicle Case Report and Review of the Literature
por: Tosev, Georgi, et al.
Publicado: (2016)

Personalized Prediction of Patient Radiation Exposure for Therapy of Urolithiasis: An Application and Comparison of Six Machine Learning Algorithms
por: Huettenbrink, Clemens, et al.
Publicado: (2023)

GAMEC – a new intensive protocol for untreated poor prognosis and relapsed or refractory germ cell tumours
por: Shamash, J, et al.
Publicado: (2007)

GAMEC – a new intensive protocol for untreated poor prognosis and relapsed or refractory germ cell tumours
por: Shamash, J, et al.
Publicado: (2007)

Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol
por: Schubert, Maria-Luisa, et al.
Publicado: (2019)

GCT-20. Multi-Institutional Analysis of Pediatric Relapsed/Refractory Central Nervous System Germ Cell Tumors
por: Nagabushan, Sumanth, et al.
Publicado: (2022)

Successful “on‐demand” plerixafor for autologous peripheral blood stem‐cells transplantation for relapsed/refractory germ cell tumors
por: Corbingi, Andrea, et al.
Publicado: (2021)

Targeting the Proteasome in Advanced Renal Cell Carcinoma: Complexity and Limitations of Patient-Individualized Preclinical Drug Discovery
por: Li, Jielin, et al.
Publicado: (2021)

Digital Spatial Profiling Identifies the Tumor Periphery as a Highly Active Biological Niche in Clear Cell Renal Cell Carcinoma
por: Schneider, Felix, et al.
Publicado: (2023)

Peritoneal carcinosis in male germ cell tumor patients: a registry study compiled by the German Testicular Cancer Study Group (GTCSG)
por: Seidel, Christoph, et al.
Publicado: (2022)

Significance of the Intraoperative Methylene Blue Test for Postoperative Evaluation of the Vesicourethral Anastomosis
por: Nyarangi-Dix, J. N., et al.
Publicado: (2012)

Genomic features of renal cell carcinoma with venous tumor thrombus
por: Warsow, Gregor, et al.
Publicado: (2018)

P1398: AXICABTAGENE CILOLEUCEL VERSUS TISAGENLECLEUCEL CAR-T CELLS IN RELAPSED OR REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
por: Gagelmann, Nico, et al.
Publicado: (2023)

Hematopoietic stem cell mobilization strategies to support high-dose chemotherapy: A focus on relapsed/refractory germ cell tumors
por: Porfyriou, Eleni, et al.
Publicado: (2021)

BAP1 and PTEN mutations shape the immunological landscape of clear cell renal cell carcinoma and reveal the intertumoral heterogeneity of T cell suppression: a proof-of-concept study
por: Friedhoff, Jana, et al.
Publicado: (2022)

Relapsed and/or Refractory Mantle Cell Lymphoma: What Role for Temsirolimus?
por: Kirschey, Sebastian, et al.
Publicado: (2012)

Primary melanoma of the prostate: case report and review of the literature
por: Tosev, Georgi, et al.
Publicado: (2015)

Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group
por: Kollmannsberger, C, et al.
Publicado: (2002)

Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group
por: Powles, T, et al.
Publicado: (2003)

High-dose therapy including carboplatin adjusted for renal function in patients with relapsed or refractory germ cell tumour: outcome and prognostic factors.
por: Lyttelton, M. P., et al.
Publicado: (1998)

Spatial niche formation but not malignant progression is a driving force for intratumoural heterogeneity
por: Hoefflin, Rouven, et al.
Publicado: (2016)

Clonal analyses of refractory testicular germ cell tumors
por: Barrett, Michael T., et al.
Publicado: (2019)

Radiopharmaceuticals for Relapsed or Refractory Leukemias
por: Kunos, Charles A., et al.
Publicado: (2019)

Relapsed/Refractory Hodgkin Lymphoma
por: Sheikh, Semira, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_mn899dg0imb8m422uun678705t